Company Announcement
The share buy-back program is expected to be completed no later than
The following transactions were executed under the program from
Trading Platform | No. of shares | Average price (DKK) | Total value (DKK) | ||
Accumulated through last announcement | 1,050,646 | 2,096,961,044.49 | |||
XCSE | 23,011 | 1,922.68 | |||
CEUX | 14,098 | 1,922.98 | |||
AQEU | 2,253 | 1,923.82 | |||
TQEX | 2,049 | 1,923.69 | |||
Total | 41,411 | 1,922.89 | 79,628,996.56 | ||
XCSE | 21,124 | 1,899.59 | |||
CEUX | 12,897 | 1,901.27 | |||
AQEU | 1,864 | 1,901.34 | |||
TQEX | 2,040 | 1,900.01 | |||
Total | 37,925 | 1,900.27 | 72,067,773.88 | ||
XCSE | 41,269 | 1,847.37 | |||
CEUX | 15,924 | 1,846.80 | |||
AQEU | 2,777 | 1,847.59 | |||
TQEX | 2,424 | 1,846.85 | |||
Total | 62,394 | 1,847.21 | 115,254,839.46 | ||
XCSE | 43,221 | 1,836.45 | |||
CEUX | 16,725 | 1,841.09 | |||
AQEU | 2,860 | 1,838.18 | |||
TQEX | 2,491 | 1,840.61 | |||
Total | 65,297 | 1,837.87 | 120,007,508.39 | ||
XCSE | 42,380 | 1,831.17 | |||
CEUX | 16,687 | 1,828.05 | |||
AQEU | 2,914 | 1,831.48 | |||
TQEX | 2,431 | 1,822.13 | |||
Total | 64,412 | 1,830.04 | 117,876,227.30 | ||
Total | 271,439 | 504,835,345.59 | |||
Accumulated under the program | 1,322,085 | 2,601,796,390.08 |
Details of each transaction are included as an appendix to this announcement.
Following these transactions,
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated
About
Established in 1999,
Contact:
T: +1 609 524 0065; E: mmp@genmab.com
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the
Company Announcement no. 44
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Carl Jacobsens Vej 30
2500 Valby
Attachments
- 240617_CA44_Transactions in connection with SBBP
- 240617_Appendix_SBBP Transactions
June 10-14
© OMX, source